Cancer cells possess a unique capacity to alter their metabolic pathways, enabling them to thrive in unfavorable environments. This phenomenon, termed metabolic reprogramming, represents a crucial driver in cancer development and progression. Consequently, targeting these altered metabolic pathways presents a promising strategy for novel cancer the